Login
$DFTX
$30.16 -$1.92 (5.99%) Live

$DFTX 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

14 Sep 2026 8-K: Regulation FD Disclosure; Other Events

This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “ou r” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solic...

08 Sep 2026 8-K: Other Events

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

12 Aug 2026 8-K: Regulation FD Disclosure; Other Events

This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “ou r” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solic...

06 Aug 2026 8-K: Results of Operations and Financial Condition

Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robust, and durable efficacy

24 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Definium Therapeutics, Inc., a corporation incorporated under the laws of the Province of British Columbia (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “...

22 Jun 2026 8-K: Regulation FD Disclosure; Other Events

This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “ou r” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solic...

12 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

WHEREAS, Definium Therapeutics, Inc. (the “Company”) maintains the Definium Therapeutics, Inc., 2025 Equity Incentive Plan, effective as of June 12, 2025 (as may be amended and restated from time to time, the “Plan”);

19 May 2026 8-K: Other Events

This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “our” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solici...

12 May 2026 8-K: Other Events

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

07 May 2026 8-K: Results of Operations and Financial Condition

Three Phase 3 topline data readouts for DT120 ODT expected in the coming months

22 Apr 2026 8-K: Other Events

This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “our” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solici...

26 Feb 2026 8-K: Results of Operations and Financial Condition

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

29 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

On January 28, 2026, the Board of Directors (the “Board”) of Definium Therapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from six (6) to seven ...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Of a Document filed with the Province of British Columbia Registrar of Companies

06 Nov 2025 8-K: Results of Operations and Financial Condition; Other Events

-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)--

31 Oct 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the ...

29 Oct 2025 8-K: Results of Operations and Financial Condition; Other Events

2 This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “ou r” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a sol...

04 Sep 2025 8-K: Other Events

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder...

31 Jul 2025 8-K: Results of Operations and Financial Condition; Other Events

--Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)--

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support